Sarepta Therapeutics (SRPT) Gets a Hold from Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target of $17.00. The company’s shares closed yesterday at $16.32.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Clark-Gartner covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Sarepta Therapeutics, and Ascendis Pharma. According to TipRanks, Clark-Gartner has an average return of 23.6% and a 61.03% success rate on recommended stocks.

In addition to Evercore ISI, Sarepta Therapeutics also received a Hold from TipRanks – Google’s Google Biotechnology in a report issued yesterday. However, on the same day, H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (NASDAQ: SRPT).

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $442.93 million and a GAAP net loss of $282.85 million. In comparison, last year the company earned a revenue of $658.41 million and had a net profit of $159.05 million

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in December 2025, Ian Michael Estepan, the COO of SRPT sold 13,187.00 shares for a total of $294,201.97.